Mild Cognitive Impairment Market Is Predicted To Advance At A CAGR Of 11.6% By 2034 Delveinsight
The United States accounted for the highest market size of MCI, approximately 52% of the total market size in 7MM in 2023, in comparison to the other major markets, i.e., EU4 countries (Germany, ...
DelveInsight Business Research, LLP: Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight
According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024-2034), owing to the rise in the launch of emerging therapies ...
FierceBiotech10h
Scribe slims down workforce as it readies cardiometabolic genetic meds for clinic
Scribe Therapeutics is slimming down its workforce by 20% as it readies its cardiometabolic pipeline for the clinic, a ...
STAT12h
Scribe Therapeutics becomes latest CRISPR company to announce layoffs
Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of ...
BioPharma Dive14h
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results
The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...
2024 Research Report: Global Celiac Disease Treatment Market Projected to Reach $2.24 Billion by 2035 with a CAGR of 11.84%
The "Celiac Disease Treatment Market by Treatment, by Route of Administration, by Distribution Channel, and By Region" report ...
1cBio and Alesta Therapeutics Announce Exclusive Global Licensing Agreement for a Novel Potentially First-in-Class Small Molecule for Hypophosphatasia
Bio, Inc. ("1cBio") an emerging biotech company developing precision medicines for significant unmet needs, and Alesta Pharmaceuticals ("Alesta") a leader in developing first-in-class small molecules ...